---
title: "002030.SZ (002030.SZ) — 相关新闻"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/002030.SZ/news.md"
symbol: "002030.SZ"
name: "002030.SZ"
parent: "https://longbridge.com/zh-CN/quote/002030.SZ.md"
datetime: "2026-03-14T08:47:17.709Z"
locales:
  - [en](https://longbridge.com/en/quote/002030.SZ/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/002030.SZ/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/002030.SZ/news.md)
---

> 支持的语言: [English](https://longbridge.com/en/quote/002030.SZ/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/002030.SZ/news.md)


# 002030.SZ (002030.SZ) — 相关新闻

### [Zhongtai Securities: Draft of the Guidelines for Project Approval in Inspection Issued, Innovation Testing Allows for Additional Charges, AD Biomarker Testing Listed](https://longbridge.com/zh-CN/news/278989746.md)
*2026-03-13T05:53:08.000Z*
> Zhongtai Securities released a research report stating that the National Healthcare Security Administration's "Guideline

### [The monkeypox sector weakens, DAJY hits the limit down](https://longbridge.com/zh-CN/news/274098071.md)
*2026-01-29T06:08:06.000Z*
> The monkeypox sector weakened, with DAJY hitting the limit down, followed by declines in Hybribio Biotech, Bohui Innovat

### [Onara Regeneration completes tens of millions of yuan in angel round financing, promoting technological breakthroughs in the field of regenerative medicine](https://longbridge.com/zh-CN/news/274072046.md)
*2026-01-29T01:44:32.000Z*
> Zhuhai Hengqin Ona Regenerative Medicine Co., Ltd. has completed tens of millions of RMB in angel round financing, led b

### [DAJY: Can provide a comprehensive solution for Nipah virus pathogen detection](https://longbridge.com/zh-CN/news/273958283.md)
*2026-01-28T08:33:46.000Z*
> DAJY announced on the interactive platform that it has provided a comprehensive solution for the Nipah virus pathogen de

### [DAJY: Stock has deviated from the increase for 2 consecutive days by over 22%, warning of multiple risks](https://longbridge.com/zh-CN/news/273831337.md)
*2026-01-27T10:57:47.000Z*
> DAJY announced that due to the stock's cumulative increase of 22.05% over two consecutive days, it constitutes an abnorm

### [](https://longbridge.com/zh-CN/news/273649643.md)
*2026-01-26T05:15:09.000Z*
> The A-share biopharmaceutical sector continues to strengthen, with Maccura, Hybribio Biotech, and KHB hitting the daily 

### [](https://longbridge.com/zh-CN/news/273632445.md)
*2026-01-26T01:33:26.000Z*
> The A-share influenza sector rose at the beginning of the trading session, with DAJY hitting the daily limit, maccura an

### [DAJY's revenue has declined continuously, and it has repeatedly cut R&D expenses to improve efficiency. Guangzhou Pharmaceutical Group plans to take over for 900 million yuan, which may turn losses into profits](https://longbridge.com/zh-CN/news/266649281.md)
*2025-11-20T01:27:43.000Z*
> Guangyao Group plans to control approximately 374 million shares of DAJY through indirect equity transfer and direct agr

### [DAJY, which is experiencing performance losses, is set to change its indirect controlling shareholder](https://longbridge.com/zh-CN/news/266495676.md)
*2025-11-19T07:39:15.000Z*
> Guangyao Group will become an indirect controlling shareholder of DAJY. According to the announcement released by DAJY,